Novartis Q3 Profit Sinks 70% Despite Sales Growth; Lifts FY26 Core Income View, Backs Sales Outlook
Novartis (NVS) reported a 70% Q3 profit decline due to impairment charges and higher expenses, but sales grew 4%. Core income rose 8%, and the company raised its FY26 core income guidance while maintaining sales growth outlook. Key growth drivers included Kisqali, Kesimpta, and Leqvio, while Cardiovascular sales declined.
How this was made
The 30-second read
Why it matters
The earnings miss drives short‑term risk, but the raised FY core income outlook may attract long‑term investors.
Market read
Significant for pharma investors; the mixed earnings and guidance update could influence trading in ADRs and sector ETFs.
What to watch
The impairment charge is a one‑off event; underlying sales growth remains solid, especially in oncology.
Background
Novartis Q3 earnings release with detailed segment performance and clinical updates.
Ticker impact
Novartis reported a 70% profit decline for Q3 but raised full-year core operating income guidance.
likely modest downside as market prices in the earnings miss, tempered by guidance upgrade
The earnings miss is material, yet the guidance lift provides a counterbalance; traders may hedge or wait for price reaction.
Market effects
Healthcare sector may see slight pressure as a large pharma reports a profit miss, but guidance lift could support peers with similar pipelines.
European markets may react modestly; US ADRs could see a small dip.
Limited to pharma and biotech investors; no broad macro impact.
Counterpoint
The guidance upgrade suggests the miss is a temporary blip; buying on dip could capture upside if pipeline progresses.
Key entities
- companyNovartis AG
Swiss pharmaceutical giant reporting Q3 results.
